Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same
AssigneesShangong Luye Pharmaceutical Co., Ltd., Youxin Li
InventorsYouxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
Claims16
A crystal form I of [4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride], wherein the crystal form I exhibits a powder X-ray diffraction pattern obtained using CuKα radiation and having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 10.690, 14.290, 16.030, 17.931, 19.009, 21.009 and 22.350.
A crystal form II of [4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride], wherein the crystal form II exhibits a powder X-ray diffraction pattern obtained using CuKα radiation and having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 5.899, 11.799, 14.481, 15.440, 18.420, 19.800 and 23.620.
A pharmaceutical composition comprising [4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride] in any one or a combination of crystal form I or crystal form II, and a pharmaceutically acceptable carrier, wherein the crystal form I exhibits a powder X-ray diffraction pattern obtained using CuKα radiation and having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 10.690, 14.290, 16.030, 17.931, 19.009, 21.009 and 22.350, and wherein the crystal form II exhibits a powder X-ray diffraction pattern obtained using CuKα radiation and having characteristic peaks expressed in degrees 2θ (±0.2° 2θ) at 5.899, 11.799, 14.481, 15.440, 18.420, 19.800 and 23.620.
Dependencies are inferred from the claim text.